Physician profile
Dacodah Labarge
NPI 1699252650
$1,007.14
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $97.13 · 2023: $21.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.15 | 2021 | |
| Clarus Therapeutics INC. | $148.58 | 2021 | |
| Lilly USA, LLC | $100.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.48 | 2021 | |
| Merck Sharp & Dohme LLC | $61.57 | 2021 | |
| Antares Pharma, INC. | $61.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $56.94 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.25 | 2021-2022 | |
| Mylan Specialty L.P. | $31.54 | 2022 | |
| Indivior INC. | $27.37 | 2021 | |
| Amgen INC. | $21.94 | 2021 | |
| Organon LLC | $21.93 | 2023 | Nexplanon |
| Alkermes, INC. | $20.92 | 2022 | |
| Novo Nordisk INC | $18.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $15.74 | 2021 | |
| Fidia Pharma USA INC. | $15.72 | 2021 | |
| Glaxosmithkline, LLC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dacodah Labarge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.